Anti-RELN/ ETL7/ LIS2 monoclonal antibody

Anti-RELN/ ETL7/ LIS2 antibody for FACS & in-vivo assay

Target products collectionGo to RELN/RELN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2292-Ab-1/ GM-Tg-hg-MP2292-Ab-2Anti-Human RELN monoclonal antibodyHuman
GM-Tg-rg-MP2292-Ab-1/ GM-Tg-rg-MP2292-Ab-2Anti-Rat RELN monoclonal antibodyRat
GM-Tg-mg-MP2292-Ab-1/ GM-Tg-mg-MP2292-Ab-2Anti-Mouse RELN monoclonal antibodyMouse
GM-Tg-cynog-MP2292-Ab-1/ GM-Tg-cynog-MP2292-Ab-2Anti-Cynomolgus/ Rhesus macaque RELN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2292-Ab-1/ GM-Tg-felg-MP2292-Ab-2Anti-Feline RELN monoclonal antibodyFeline
GM-Tg-cang-MP2292-Ab-1/ GM-Tg-cang-MP2292-Ab-2Anti-Canine RELN monoclonal antibodyCanine
GM-Tg-bovg-MP2292-Ab-1/ GM-Tg-bovg-MP2292-Ab-2Anti-Bovine RELN monoclonal antibodyBovine
GM-Tg-equg-MP2292-Ab-1/ GM-Tg-equg-MP2292-Ab-2Anti-Equine RELN monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2292-Ab-1/ GM-Tg-hg-MP2292-Ab-2; GM-Tg-rg-MP2292-Ab-1/ GM-Tg-rg-MP2292-Ab-2;
GM-Tg-mg-MP2292-Ab-1/ GM-Tg-mg-MP2292-Ab-2; GM-Tg-cynog-MP2292-Ab-1/ GM-Tg-cynog-MP2292-Ab-2;
GM-Tg-felg-MP2292-Ab-1/ GM-Tg-felg-MP2292-Ab-2; GM-Tg-cang-MP2292-Ab-1/ GM-Tg-cang-MP2292-Ab-2;
GM-Tg-bovg-MP2292-Ab-1/ GM-Tg-bovg-MP2292-Ab-2; GM-Tg-equg-MP2292-Ab-1/ GM-Tg-equg-MP2292-Ab-2
Products NameAnti-RELN monoclonal antibody
Formatmab
Target NameRELN
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-RELN benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species RELN/ ETL7/ LIS2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2292
    Target NameRELN
    Gene ID5649,19699,24718,696372,483273,101085703,281450,100058621
    Gene Symbol and SynonymsETL7,LIS2,PRO1598,Reelen,reeler,RELN,RL
    Uniprot AccessionP78509,P58751,Q9N117
    Uniprot Entry NameRELN_HUMAN,RELN_RAT,RELN_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    Diseasebipolar disorder, Autism, major depression, schizophrenia
    Gene EnsemblENSG00000189056
    Target ClassificationN/A

    The target: RELN, gene name: RELN, also named as ETL7, LIS2, PRO1598, RL. This gene encodes a large secreted extracellular matrix protein thought to control cell-cell interactions critical for cell positioning and neuronal migration during brain development. This protein may be involved in schizophrenia, autism, bipolar disorder, major depression and in migration defects associated with temporal lobe epilepsy. Mutations of this gene are associated with autosomal recessive lissencephaly with cerebellar hypoplasia. Two transcript variants encoding distinct isoforms have been identified for this gene. Other transcript variants have been described but their full length nature has not been determined. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.